Scientists Found 2 Existing Drugs Can Reverse Alzheimer's Brain Damage in Mice

US researchers have identified two existing, FDA-approved cancer drugs, letrozole and irinotecan, as promising candidates for treating Alzheimer's disease, potentially accelerating clinical trials. Leveraging computational analysis of gene expression and patient data, the study found that a combination of these drugs reversed brain changes, reduced tau protein, and improved cognitive function in mouse models by targeting different cell types. This discovery offers a novel approach to drug repurposing for complex neurodegenerative conditions like Alzheimer's, which affects over 55 million people globally, presenting a significant market opportunity for effective treatments, though human clinical trials and side effect considerations are the next crucial steps.

Analysis

A 2025 study published in Cell identified two existing FDA-approved cancer drugs, letrozole and irinotecan, as promising candidates for Alzheimer's disease treatment. Researchers utilized computational tools to analyze gene expression changes in Alzheimer's brains, then cross-referenced medical databases and patient records to find drugs that reversed these changes. This innovative approach leverages existing pharmaceuticals, potentially expediting the drug development timeline.

In mouse models, the combined administration of letrozole and irinotecan significantly reduced harmful tau protein clumps and improved learning and memory tasks, key indicators of Alzheimer's progression. The drugs demonstrated a synergistic effect by targeting different brain cell types, with letrozole acting on neurons and irinotecan on glia, addressing the disease's complex multi-gene alterations. This dual-action mechanism offers a novel therapeutic pathway.

This discovery holds substantial implications for the Alzheimer's market, which currently affects over 55 million people globally and is projected to double within 25 years. Repurposing existing drugs could lead to more personalized and effective treatments, offering a significant opportunity given the high unmet medical need. While promising, the next critical step involves human clinical trials to assess efficacy and manage known side effects.

Key Decisions for Investors

• Monitor the initiation and progress of human clinical trials for letrozole and irinotecan in Alzheimer's, as successful outcomes could significantly impact companies holding intellectual property or manufacturing rights for these compounds.
• Evaluate the potential competitive landscape shift within the Alzheimer's drug development sector, considering how drug repurposing could accelerate new treatment options and challenge traditional R&D pipelines.
• Assess the broader investment implications for biotech firms specializing in computational drug discovery and repurposing platforms, given the demonstrated success of this methodology in identifying new therapeutic applications for existing drugs.